Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863407 | 1.00 | DPP4 (0.59) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2853150 | 0.95 | DPP4 (0.60) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2855977 | 0.95 | DPP4 (0.60) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2855601 | 0.94 | DPP4 (0.59) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3111827 | 0.94 | DPP4 (0.59) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2859990 | 0.94 | DPP4 (0.59) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL13175403 | 0.94 | DPP4 (0.59) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2859987 | 0.94 | DPP4 (0.59) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2853128 | 0.93 | DPP4 (0.58) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2853129 | 0.93 | DPP4 (0.58) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230241-B1 | TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2014-11-26 | — | — | EP | disclosed |
| US-8513411-B2 | Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-8207161-B2 | Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2012-06-26 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| EP-2230241-A1 | TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-09-22 | — | — | EP | disclosed |
| CN-101641361-A | Tetrahydroimidazo [1, 5-a ] pyrazine derivative, preparation method and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD | 2010-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 7/4885 |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.